Research programme: anti-alpha folate receptor monoclonal antibody - Dompe

Alternative Names: AFRA; Anti-α-FR Mab; FabOvar

Latest Information Update: 30 Jan 2018

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dompe Farmaceutici
Developer Advanced Accelerator Applications; Dompe Farmaceutici
Class Monoclonal antibodies
Mechanism of Action Folate receptor 1 antagonists; Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

01 Feb 2018 Advanced Accelerator Applications has been acquired by Novartis
29 Jun 2016 Discontinued - Preclinical for Ovarian cancer in Italy (Parenteral)
01 Aug 2011 FabOvar licensed to Advanced Accelerator Applications

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com